MedTrace Logo

Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules

NCT03405805 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-01-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the establishment of immunological memory between the 3 different infant vaccination schedules with the 13-valent pneumococcal conjugate vaccine (PCV13) currently in use. We aim to determine the optimal schedule for the establishment of antigen-specific memory B-cell pool, which may serve as a correlate for longevity of immunological memory against vaccine serotypes. Moreover, we will study the transcriptome profiles expressed by peripheral lymphocytes during each immune response in an attempt to reveal immunological mechanisms beyond the antibody and circulating B cells level.

Conditions

  • Immunogenicity, Vaccine
  • Immunologic Memory

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine (PCV13)

Vaccination with PCV13

Sponsors & Collaborators

  • Aghia Sophia Children's Hospital of Athens

    lead OTHER

Principal Investigators

  • Vana Spoulou, MD, PhD · "Aghia Sophia" Children's Hospital

Eligibility

Min Age
2 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-12
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03405805 on ClinicalTrials.gov